Neuroscientific Biopharmaceuticals soars on stem cell tech results
Adding extra weight to the outcome, these treatments were administered in the real world, where advanced disease does not follow a script, rather than in a sanitized laboratory trial designed for perfect data. According to the company, this challenging clinical environment gave the results even greater impact and offered a clear window into how StemSmart can perform under everyday conditions.
Management says the result is more than just a checkmark for the StemSmart platform. It also confirms the company’s $5.1 million move last June to acquire unlisted Perth-based stem cell specialist Isopogen, which is the original owner of the intellectual property behind the therapy.
Nathan Smith, CEO of NeuroScientific Biopharmaceuticals, said: “These treatment results provide critical validation that the StemSmart MSC platform can offer a potential therapeutic solution to patients with debilitating fistulizing Crohn’s disease. These data, together with our previous clinical trial results in refractory Crohn’s disease, provide a strong foundation for our future commercialization plans of StemSmart.”
Dr Cathy Cole, chief medical officer of NeuroScientific Biopharmaceuticals, added: “The rate of response to StemSmart MSC therapy seen in a real-world setting in these patients is remarkable and offers hope for clinical improvement where there was previously very little.”
Now that strong, early validation signals are in place, NeuroScientific says it is shifting its focus to the next phase of implementation. Encouraging signals from previous phase two studies in refractory Crohn’s disease have already indicated strong efficacy and safety, and the latest real-world data reinforce this further.
The company plans to incorporate these insights directly into the design of its next round of clinical trials, planned for the second half of this year. Behind the scenes, the heavy lifting has already begun, with production scaling-up, regulatory planning and trial development moving in parallel to maintain momentum.
While Crohn’s disease alone represents a global market worth approximately US$13 billion, NeuroScientific believes the StemSmart platform has much broader potential. The company envisions the technology expanding into broader anti-inflammatory and immune-modulating applications, with possible pathways into organ transplant tolerance, lung inflammatory diseases, and graft-versus-host disease.
In an industry where promise is often far ahead of evidence, NeuroScientific appears to be bridging that gap. Real-world results, a clear clinical path and a platform technology with multiple shots on target are now in order.
If the company can carry this momentum into the next round of trials, StemSmart could quickly move from an encouraging experiment to a world-class biotech growth story.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
